AnaSpec to Manufacture BD™ Fluorescent Dyes for BD Biosciences
News Sep 18, 2008
“BD Biosciences has a tremendous reputation in the industry for innovative products of the highest quality,” stated Dr. Anita Hong, AnaSpec’s president. “We are proud to leverage AnaSpec’s fluorescent dye technology in the production of these novel dyes.”
H7 is the abbreviation of HiLyte Fluor™ 750 Bis-NHS ester, which carries two amine-reactive groups, succinimidyl esters, on each dye molecule for general labeling of protein amine groups.
BD APC-H7 is a tandem conjugate and an analog of APC-CyTM7 with the same spectral properties. It has decreased intensity but it is engineered for greater stability and less spillover in the APC channel and consequently offers better performance than APC-Cy7. It has an absorption maximum of approximately 650 nm. When excited by light from a red laser, the APC fluorochrome can transfer energy to the cyanine dye, which then emits at a longer wavelength. The resulting fluorescent emission maximum is approximately 767 nm.
The cell viability indicator calcein AM, is a non-fluorescent, cell permeant compound that is hydrolyzed by intracellular esterases into the fluorescent anion calcein. BD™ Calcein AM Fluorescent Dyes can be used to fluorescently pre- and post-label viable cells to perform kinetic and endpoint experiments, respectively.
DiIC12 is a lipophilic neuronal tracer, which is commonly used for the labeling of neuronal projections as well as lipid bilayers in other cell types. Since DiIC12 exhibits low toxicity and minimal effects on cell viability, this dye can be used to pre-label cells for a variety of applications.
BD™ DiIC12 Fluorescent Dye can be used to fluorescently label viable cells for assays, such as tumor cell invasion or endothelial cell migration. Moreover, cells are known to tolerate different fluorescent dyes for varying amounts of time in culture. While cells labeled with calcein AM should be exposed to the dye for less than eight hours, DiIC12 can be used for several days in culture without adversely affecting cells.
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Improved Method for Isolating Extracellular RNANews
In a breakthrough that could lead to powerful new ways to diagnose and track a wide range of medical conditions, scientists at The Rockefeller University have devised an improved method for isolating and identifying tiny fragments of RNA in human blood products.READ MORE
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.